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ABSTRACT
Introduction: Multidrug-resistant tuberculosis (MDR-
TB) poses a serious financial challenge to health
systems and patients. The current treatment for
patients with MDR-TB takes up to 24 months to
complete. Evidence for a shorter regimen which differs
from the standard WHO recommended MDR-TB
regimen and typically lasts between 9 and 12 months
has been reported from Bangladesh. This evaluation
aims to assess the economic impact of a shortened
regimen on patients and health systems. This
evaluation is innovative as it combines patient and
health system costs, as well as operational modelling
in assessing the impact.
Methods and analysis: An economic evaluation
nested in a clinical trial with 2 arms will be performed
at 4 facilities. The primary outcome measure is
incremental cost to the health system of the study
regimen compared with the control regimen.
Secondary outcome measures are mean incremental
costs incurred by patients by treatment outcome;
patient costs by category (direct medical costs,
transport, food and accommodation costs, and cost of
guardians/accompanying persons and lost time); health
systems cost by category and drugs; and costs related
to serious adverse events.
Ethics and dissemination: The study has been
evaluated and approved by the Ethics Advisory Group
of the International Union Against Tuberculosis and
Lung Disease; South African Medical Research Ethics
Committee; Wits Health Consortium Protocol Review
Committee; University of the Witwatersrand Human
Research Ethics Committee; University of Kwazulu-
Natal Biomedical Research Ethics Committee; St Peter
TB Specialized Hospital Ethical Review Committee;
AHRI-ALERT Ethical Review Committee, and all
participants will provide written informed consent. The
results of the economic evaluation will be published in
a peer-reviewed journal.
Trial registration number: ISRCTN78372190.
BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) is
a form of tuberculosis resistant to isoniazid
(INH) and rifampicin, two of the most
important ﬁrst-line TB drugs.1 2 The WHO
estimates that, globally in 2012, over 450 000
people developed MDR-TB, and 170 000
people died of MDR-TB.1–3 In contrast to
drug-susceptible TB, which is treatable in
6 months, patients with MDR-TB are treated
for a minimum of 20 months. The costs of
treating MDR-TB are much greater than treat-
ing drug-susceptible TB, from a health
systems and patient perspective.4 For instance,
health systems cost per patient for MDR-TB
treatment in Estonia, Peru, the Philippines
and Tomsk was US$10 880, US$2423, US
$3613 and US$14 657, respectively.5 Similarly,
in South Africa, the average health systems
cost of inpatient treatment for MDR-TB
exceeded US$17 000, nearly 40 times the
average cost of treating drug-susceptible TB.6
Strengths and limitations of this study
▪ STREAM enrols multidrug-resistant tuberculosis
patients (an understudied but highly burdened
population) into trial treatment regimens and
economic evaluation will determine health
system costs, out-of-pocket payments and finan-
cial coping mechanisms in this population.
▪ Health system and patient costs will be collected
and analysed for budget impact and economic
burden, respectively.
▪ Collecting data from participants across coun-
tries and at multiple time points has inherent
challenges, including loss to follow-up and par-
ticipant heterogeneity.
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From a patient perspective, a recent systematic review on
the ﬁnancial burden for tuberculosis patient in low-
income and middle-income countries has shown that the
total cost for patients with MDR-TB is considerably higher
than drug-susceptible TB.7 For instance, the total costs as
percentage of reported individual income for patients
with MDR-TB and patients with drug-susceptible TB in
Ecuador and Cambodia were 223% ($14 388) vs 31%
($2008) and 76% (2953) vs 24% ($923), respectively.7
An observational research study from Bangladesh by
Van Deun et al8 concluded that shorter standardised treat-
ment regimens lasting up to 12 months are as effective in
treating MDR-TB as the current 22-month regimen.
Similarly, treatment standardisation has also been advo-
cated as a feasible and potentially effective approach for
MDR-TB,9 10 but this has not been evaluated in a clinical
trial with a nested economic analysis. While shortening
treatment regimens might be expected to reduce costs,
this is far from certain. Analysis of patient costs during
drug-sensitive tuberculosis treatment in Bangladesh and
Tanzania11 suggests that these costs are not incurred stead-
ily over the course of treatment, but occur disproportion-
ately during the intensive phase, implying that cost savings
from the shortened regimen may be limited. There is also
the potential for increased adverse events in the shortened
regimen, which have cost implications. Even if shortened
regimens are cost saving overall, detailed information on
the nature and timing of costs to patients and health
systems is required to inform the planning and delivery of
TB services and social protection programmes.
This study therefore aims to assess the economic impact
on patients and health systems of the shortened standar-
dised regimen as proposed in the Bangladesh study (study
regimen) compared to the locally used WHO-approved
MDR-TB (control regimen). The results of this evaluation
will provide granular information on the types of costs
associated with MDR-TB treatment from a patient and
health system perspective, and how adopting shortened
regimens will affect the amount and timing of these costs.
It will identify the major drivers of these costs and thereby
provide a starting point for work to reduce these costs,
where possible, without compromising safety or effective-
ness. The evaluation will therefore assist decisions about
the planning and uptake of shortened MDR-TB treatment
regimens in different settings. To achieve this, the eco-
nomic evaluation will establish the cost associated with the
study and control regimens,8 including costs related to
serious adverse events (SAE). A societal perspective will be
taken, so that health systems and patient costs are
included.12 A full description of the main trial and its
com-ponents is described in the main trial protocol.13
In this paper, our focus is on the costing methodology of
the economic evaluation.
OBJECTIVES
The main objective of the economic evaluation is to
document how a shortened MDR-TB treatment regimen
compared to the control regimen will affect the amount,
nature and timing of costs incurred by patients and by
the health system with the aim of informing programme
management and the design of interventions for patient
ﬁnancial protection.8
The speciﬁc objectives of the health economic compo-
nent in the trial are therefore: (Gospodarevskaya E. The
evaluation of a standardised treatment regimen of anti-
tuberculosis drugs for patients with MDR-TB (STREAM).
Health Economics Guide, 2012,Unpublished guide):
A. To assess the costs incurred by patients enrolled in the
study regimen when compared to the control regimen.
B. To assess the costs incurred by the health system for
the study regimen when compared to the control.
C. To describe the types of costs incurred by patients
and health systems in the management of MDR-TB.
D. To identify the main drivers of costs in the manage-
ment of MDR-TB.
METHODS AND DESIGN
Study design
An economic evaluation comparing two arms: study
regimen and control or locally used WHO-approved
MDR-TB regimen. The study regimen is a modiﬁed
version of the 9-month regimen based on the one
described by Van Deun et al8 and consists of ethambutol,
pyrazinamide, moxiﬂoxacin and clofazimine given for
9 months (40 weeks), supplemented by kanamycin,
prothionamide and INH in the ﬁrst 4 months
(16 weeks). The only change from the Bangladesh study
regimen described by Van Deun et al8 is the substitution
of gatiﬂoxacin with moxiﬂoxacin. Patients will be rando-
mised to either the study regimen or control regimen. A
detailed description of the study design is available in
the main trial protocol.13
Settings
The STREAM trial is taking place in four countries
(Ethiopia, Mongolia, South Africa and Vietnam);
however, due to research clearance challenges, the eco-
nomic evaluation will be conducted in two countries
(Ethiopia and South Africa). In Ethiopia, the study will
be conducted at two major referral health facilities in
Addis Ababa. In South Africa, the study will be con-
ducted in two different locations, Johannesburg and
Pietermaritzburg, and one healthcare facility in each
location. The selection of facilities in each country is
based on their experience in treating patients with
MDR-TB and support from the Tuberculosis Control
Programme at national or regional level and suitable
treatment site staff and facilities.
Sampling
The sample size for the overall study is 400 calculated
on the basis of expected difference in proportion of
favourable clinical outcomes between the control
regimen and study regimen with 95% CIs.13 Since the
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level of patient costs and the expected change as a result
of the study regimen is unknown, it is not possible to
make an accurate assessment of required sample size for
the patient costing survey. A target of 100 patients per
country has been selected based on a study by
Management Science for Health14 which found this to
give a reasonable spread of costs in similar studies in
Ethiopia. In addition, a recent study investigating
patients’ costs during TB treatment in Bangladesh and
Tanzania used a sample of about 100 patients per
country.11 It is recognised that in countries with lower
recruitment rates, this may represent 100% of the study
population; in these cases, it is accepted that some
patients may choose not to participate in the costing
study and that fewer cases, and hence greater uncertainty
in the estimates, may be found. Despite this, an economic
evaluation can still provide valuable information about
costs and beneﬁts of the study regimens.15 However, to
ensure full participation, the trial will employ all neces-
sary measures aimed at reducing or avoiding drop-out
due to patient costs. These measures will include provid-
ing ﬁnancial support to cater for food, accommodation
and transport in both arms of the study.
INTERVENTION DESIGN
Patients randomised to the control arm will receive
usual clinical care based on the application of the
‘WHO guidelines for management of MDR-TB’.16
Patients allocated to the study regimen will be treated at
facilities that will have staff trained on the shorter stan-
dardised treatment regimen of MDR-TB. To ensure com-
parability of the two arms in terms of comorbidities, we
will use EQ5D-5L to capture health status information.
Figure 1 illustrates the pathways followed by patients in
arms and summaries of activities at various stages of the
treatment process.
OUTCOME MEASURES
The main health economics-related outcomes will be:14
▸ Mean incremental costs incurred by patients.
▸ Incremental cost to the health system of the study
regimen compared with the control regimen (savings
will be recorded as negative incremental costs).
Additional health economics outcomes will be:
▸ Mean costs incurred by patients analysed by treat-
ment outcome.
▸ Patient costs by category (direct medical costs, trans-
port, food and accommodation costs, and cost of
guardians/accompanying persons and lost time).
▸ Health systems cost by category (training, monitoring,
service delivery and drugs).
▸ Costs related to SAE.
PARTICIPANTS
The participants of this study will be patients with
MDR-TB and caregivers. Interviewers will explain to all
participants that involvement in the study is voluntary
and they have the right to withdraw at any point in time
and to ask any questions. Information about the study
will be translated to Amharic, Zulu and other local lan-
guages, and read to all participants and provided in
hard copy. In both countries, consent for the health eco-
nomics component is covered in the main study’s
consent form (ie, a separate consent form is not used).
However, we will obtain consent from health workers to
be interviewed (and recorded) and timed.
COSTING
Costs will be collected from health system and patient
perspectives, and will consider the healthcare resource
requirements and patient expenses associated with each
treatment arm. Speciﬁcally, we will collect data in two
resource use areas: (1) healthcare services costs, which
include the use of all hospital facilities over the course
of the trial, including drugs, medical supplies and
laboratory; and (2) patient out-of-pocket expenses,
which include the individual’s own time (lost time) in
the treatment process and associated travel expenses.
Health systems costs will include costs incurred at facil-
ities, by each study arm. Patient costs that will be esti-
mated are those incurred in seeking services for
MDR-TB healthcare. The trial is expected to report its
main outcomes in 2017, so all costs will be inﬂated to
2017 values using the relevant consumer price indices
from the International Monetary Fund, and converted
from local currency units to international dollars using
purchasing power parity exchange rates.
INSTRUMENTS AND MEASUREMENT OF HEALTH SYSTEM
AND PATIENT COSTS
Patient costs
Information on patients’ demographic characteristics,
socioeconomic status, household assets and
MDR-TB-related costs will be collected by administering
an adaptation of a validated questionnaire recommended
by the Stop TB partnership.17 18 Patient costs will include
out-of-pocket healthcare costs (eg, charges for diagnostic
Figure 1 Intervention design, patient pathway and key
processes.
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tests, administration fees, expenses associated with hospi-
talisation); cost of travel to health facility incurred by
patients and their guardians; and other related treatment
costs (eg, nutrition supplements). To obtain estimates of
productivity lost by patients and their caregivers who gave
up paid employment, information on their pre-MDR-TB
earnings will be collected. Patients will also be asked
about coping costs—money they borrowed or received
from selling assets to cover the cost of treatment.
Data to estimate patient costs will be collected in two
stages. First, through a baseline questionnaire at enrol-
ment to either arm, capturing demographic details such
as asset ownership. Second, patient follow-up costs ques-
tionnaire every 3 months after enrolment. The question-
naire will include questions on patient and household
costs such as fees paid to the health system, drugs and
laboratory test costs, transport, food, accommodation
costs incurred as a result of the treatment process as well
as costs incurred as a result of managing adverse events
and time lost from economic activities due to illness or
care-seeking. Various measures and sources of patient
costs are discussed and summarised in table 1.
Non-medical direct costs will include home help
received as a result of morbidity related to MDR-TB,
patient and caregivers time directly related to the inter-
vention (time spent getting to the facility, waiting room
and intervention). The patients will be asked to quantify
how much work was actually performed during regular
hours and quality of this work compared to now.
Health system costs
Information on health systems costs will be collected
from various sources. Speciﬁcally, we will collect data on
resources and costs related to personnel, clinical prac-
tice, laboratory tests, drugs and medical supplies.
Primary data on these variables will be collected and
estimated using information from budget and ﬁnancial
records maintained by health facilities in the study sites
and their related health system structures (eg, Ministry
of health subofﬁces or district hospitals). Data on the
usage of STREAM trial health services, the associated
consumption of drugs and medical supplies and time
allocated to STREAM trial care by staff in the study sites
will be collected from individual patient records and
pharmacy logs and in time allocation interviews with the
study site healthcare providers and stored in an elec-
tronic database in the context of South Africa, while in
Ethiopia, it is captured directly within an Excel spread-
sheet developed for the economic evaluation. Unit costs
for healthcare resources will be derived from local and
national sources and performed in line with best prac-
tices.19–23
Various measures of health system cost are discussed
and summarised in table 2. Medical direct costs include
those attributable to healthcare visits for the treatment
of MDR-TB: the cost of training provided to healthcare
providers; visits to primary healthcare facilities, to specia-
lists and to rehabilitation services; number of essential
tests; cost of medicines and disposable supplies as well as
hospitalisation for acute episodes of SAE.
Primary data on health system and patient costs will
be collected from from South Africa and Ethiopia. For
incremental cost analysis purposes, resource use in the
control arm will be estimated based on cost of standard
care, using information from budget and ﬁnancial
records maintained by the local hospital and their related
Ministry of Health (MOH) structures. An ingredients
approach will be taken, where the value of inputs is based
on quantities and unit prices (the ingredients). Only
incremental costs associated with the study regimen will
be included.
Staff costs will be obtained through an analysis of
health worker time involved in prescribing, monitoring
and supervising the study and control regimens at each
site. This will be obtained through interviews with health
workers involved at different stages in the treatment
pathway, including those performing diagnostic and
other tests during treatment and during the follow-up
Table 1 Description of key categories of patient costs and sources
Main variable Description Information source
Pretreatment patient
socioeconomic status
Education, employment, income, asset ownership
and socioeconomic indicators
Baseline questionnaire capturing
socioeconomic status of patient before
starting treatment
Direct and indirect costs Follow-up checks and tests, hospitalisation,
relocation, dietary supplements and treatment of
adverse events (including ancillary medicines)
Follow-up questionnaire capturing
1. Follow-up tests and related companion
costs during past 3 months
2. Hospitalisation and relocation and related
companion costs at any time during
illness
3. Dietary (nutrition) supplements during
treatment
4. Adverse events during treatment
Coping Sources of funding for patient costs, borrowing,
sales of assets, leasing of assets
Baseline and follow-up questionnaires
capturing coping strategies during diagnosis
and treatment periods
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period. The cost of this time will be based on salaries
and beneﬁts of different health workers involved. Data
will be obtained from the MOH based on grade of staff
rather than named individuals.
The costs of drugs, laboratory reagents, monitoring
stationery, equipment and other consumables will be col-
lected from study, health facility or Ministry of Health
(MOH) records, according to the procurement source.
Where possible actual costs will be used; these will be
adjusted for standard or market rates where study-
related discounts or additional costs have been incurred.
The costs of all diagnostic and follow-up tests will be col-
lected during the study. Equipment will be depreciated
over the expected life of the item. For example, 3 years
for computing equipment and 5 years for diagnostic
equipment. In all cases, a literature search will inform
the most common choices for selected depreciation
rates.12 Costs that are incurred over >1 year will be dis-
counted at the rate of 3% per annum.12 19–23
Only costs associated with implementation will be
included; any costs that are clearly necessary only for
study purposes (such as nurse time allocated to adminis-
tration of cost questionnaires) and not for routine prac-
tice will be excluded from the analysis. The effect of
including costs that were incurred for research trial
monitoring (such as intensive Holter ECG monitoring),
but may or may not be necessary for implementation
will be assessed through sensitivity analyses. Costs will be
analysed into one-time costs required for establishing
the study regimen and recurrent costs for sustaining the
study regimen. Data will be collected from at least two
study sites in each country (unless only one site is used).
Where possible, these will have different characteristics
(eg, secondary/tertiary facility; urban/rural).
Considering that medicines used in clinical trials and
practice may often have SAE which could lead to consid-
erable economic and clinical costs, the study will also
collect costs related to SAE. Costs for SAE will be esti-
mated using case reference forms, case notes and
receipts from diagnostic suppliers and hospital records.
DATA ANALYSIS
Costs will be analysed using excel and an operational
model. The evaluation will include using patient
pathway models to understand the impacts on costs and
delays of any lack of adherence to stated diagnostic and
treatment policy. This approach will provide additional
information to inform the development of policies,
guidelines and the cost-effectiveness analysis. The model
will combine information derived from the documented
patient pathways, clinical data and cost information. This
operational model will be built using discrete event
simulation following the approach previously used in
Tanzania to assist policy decisions on TB diagnostics.24
Uncertainty in the estimated costs due to uncertainty
to cost input parameter values will be evaluated by
employing probabilistic sensitivity analysis using the
lower and upper bound of CIs. Speciﬁcally, sensitivity
analyses will be undertaken on the basis of price and
activity ﬂuctuations, informed by time required to com-
plete various activities in the patient pathways using the
operation model. Given the problem of using a con-
trolled trial to estimate real-world costs (the trial almost
inevitably invests more in adherence to regimen, eg,
than will be performed in practice), sensitivity analysis
will be crucial as this has implications for treatment out-
comes and costs.
Patient costs will be analysed in total and by subcat-
egory of cost (eg, medical expenses, transport) for
patients on each study regimen. Given that patient treat-
ment costs are typically positively skewed (not normally
distributed), the distribution of patient costs will be
assessed in each country. If the costs are not normally
Table 2 Description of key categories of health systems costs and sources
Type of cost Description Information source
Labour Disaggregated into cadre and type at
proportion of time spent
Staff overheads
MOH district health office, implementing partners
records and staff interviews
Transport (Ethiopia
only)
Vehicles
Fuel
Maintenance
MOH district health office, implementing partners
records and staff interviews
Capital costs Equipment
Building
Computers
MOH district health office, implementing partners
records and staff interviews
Supplies Drugs
Personal protective equipment
Other supplies
MOH district health office, implementing partners
records and staff interviews
Diagnostics Laboratory tests
X-rays
ECGs
Diagnostic firms, MOH offices, implementing partners
records and staff interviews
MOH, Ministry of Health.
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distributed, log transformations will ﬁrst be performed
to see whether this creates a normal distribution, and if
not, non-parametric tests will form the basis for the ana-
lysis. While every effort will be made to ensure complete
data collection, missing data due to loss to follow-up,
unwillingness to provide economic data or inaccurate/
incomplete completion of forms are always a possibility.
The nature and pattern of any such ‘missingness’ will be
carefully considered—including in particular whether
data can be treated as ‘missing at random’. If it is seen
as appropriate, values for missing items will be imputed
using multiple imputation routines commonly available
in standard software packages.
Further analyses will disaggregate cost by socio-
economic status and by gender of patient. Costs will be
compared with the income level of the patients for each
level of socioeconomic status. Depending on availability,
information on socioeconomic indicators will be
obtained from either local household budget survey
data or Lifestyle Monitoring Survey Data.12 19–23
DISCUSSION
This study seeks to address an important problem
related to MDR-TB which is more costly to treat com-
pared to drug-susceptible TB with ﬁnancial implication
on the health system and patients. There is a need for
improvement in the diagnosis, treatment and manage-
ment of MDR-TB. This study will provide evidence on
the resources and costs related to treatment and man-
agement of patients with MDR-TB using the short
regimen when compared to the WHO MDR-TB treat-
ment regimen and assist in policy development.
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